1 Market Overview
1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Introduction
1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast
1.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends & Drivers
1.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends
1.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers & Opportunity
1.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges
1.3.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Revenue Ranking (2024)
2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Company (2019-2025)
2.3 Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Offered
2.5 Key Companies Time to Begin Mass Production of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
2.6 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Competitive Analysis
2.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Rate (2019-2025)
2.6.2 Global 5 and 10 Largest Companies by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 PCR
3.1.2 In-situ Hybridization
3.1.3 Immunohistochemistry
3.1.4 Sequencing
3.1.5 Others
3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type
3.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (2019 VS 2024 VS 2034)
3.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Type (2019-2034)
3.2.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Type (%) (2019-2034)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Neurological Disorders
4.1.3 Cardiovascular Disease
4.1.4 Immunological Disorders
4.1.5 Others
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application
4.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (2019 VS 2024 VS 2034)
4.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Application (2019-2034)
4.2.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Application (%) (2019-2034)
5 Segmentation by Region
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region
5.1.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region: 2019 VS 2024 VS 2034
5.1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2019-2025)
5.1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2025-2034)
5.1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (%), (2019-2034)
5.2 North America
5.2.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
5.2.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2024 VS 2034
5.3 Europe
5.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
5.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2024 VS 2034
5.4 Asia Pacific
5.4.1 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
5.4.2 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2024 VS 2034
5.5 South America
5.5.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
5.5.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2024 VS 2034
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
5.6.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2024 VS 2034
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value Growth Trends, 2019 VS 2024 VS 2034
6.2 Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value
6.3 United States
6.3.1 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.3.3 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.4 Europe
6.4.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.4.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.4.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.5 China
6.5.1 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.5.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.5.3 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.6 Japan
6.6.1 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.6.2 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.6.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.7 South Korea
6.7.1 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.7.2 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.7.3 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.8 Southeast Asia
6.8.1 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.8.2 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.8.3 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
6.9 India
6.9.1 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2034
6.9.2 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2024 VS 2034
6.9.3 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2024 VS 2034
7 Company Profiles
7.1 Qiagen NV
7.1.1 Qiagen NV Profile
7.1.2 Qiagen NV Main Business
7.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.1.5 Qiagen NV Recent Developments
7.2 GE Healthcare
7.2.1 GE Healthcare Profile
7.2.2 GE Healthcare Main Business
7.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.2.5 GE Healthcare Recent Developments
7.3 Agilent Technologies
7.3.1 Agilent Technologies Profile
7.3.2 Agilent Technologies Main Business
7.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.3.5 F Hoffman La Roche Recent Developments
7.4 F Hoffman La Roche
7.4.1 F Hoffman La Roche Profile
7.4.2 F Hoffman La Roche Main Business
7.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.4.5 F Hoffman La Roche Recent Developments
7.5 Foundation Medicine
7.5.1 Foundation Medicine Profile
7.5.2 Foundation Medicine Main Business
7.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.5.5 Foundation Medicine Recent Developments
7.6 Thermo Fisher Scientific Inc.
7.6.1 Thermo Fisher Scientific Inc. Profile
7.6.2 Thermo Fisher Scientific Inc. Main Business
7.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.6.5 Thermo Fisher Scientific Inc. Recent Developments
7.7 Leica Biosystems Nussloch GmBH
7.7.1 Leica Biosystems Nussloch GmBH Profile
7.7.2 Leica Biosystems Nussloch GmBH Main Business
7.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.7.5 Leica Biosystems Nussloch GmBH Recent Developments
7.8 Pfizer
7.8.1 Pfizer Profile
7.8.2 Pfizer Main Business
7.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
7.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2025)
7.8.5 Pfizer Recent Developments
8 Industry Chain Analysis
8.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industrial Chain
8.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Model
8.5.2 Sales Channel
8.5.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
